Date: 2017-05-02
Type of information: Series A financing round
Company: ImCheck Therapeutics (France)
Investors: Boehringer Ingelheim Venture Fund (BIVF) (Germany) Kurma Partners (France) Idinvest (France) Gimv (Belfium) LSP (The Netherlands)
Amount: €20 million
Funding type: series A financing round
Planned used:
- ImCheck Therapeutics is a new privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly differentiated & diversified portfolio of first-inclass therapeutic antibodies in cancers and auto-immunity.
- The company is a spin-off from Marseille’s Institut Paoli-Calmettes (IPC), one of the leading cancer centers in Europe and developing intellectual property licensed from Inserm Transfert and SATT SE. The company was founded in 2015 around Daniel Olive (Professor of immunology at AixMarseille University (AMU) and IPC), a pioneer in innate immunity & co-signaling molecules and Head of the immune monitoring program for early stage clinical trials in oncology at IPC.
- To-date, ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, who play a defined immune-modulating role in both innate and adaptive immunity. Based in Marseille - France, within the Marseille’s Cancer Research Center (IPC, CNRS, Inserm,
AMU), ImCheck has a team of ten scientists and is engaged in an active recruitment dynamic.
Others:
- • On May 2, 2017, ImCheck Therapeutics, an emerging player in the field of cancer and auto-immunity, announced the completion of a €20 Million Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest and joined by Gimv and LSP.
- In conjunction with this financing, ImCheck appointed Pierre d’Epenoux as Chief Executive Officer. Pierre brings with him two decades of operational management and corporate development experience in pharma and biotech.
Therapeutic area: Cancer - Oncology - Immunological diseases
Is general: Yes
